Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma

Abhishek D. Parmar, Gabriela M. Vargas, Nina P. Tamirisa, Kristin M. Sheffield, Taylor S. Riall

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Introduction Multimodality therapy with chemotherapy and operative resection is recommended for patients with locoregional pancreatic cancer but is not received by many patients. Objective To evaluate patterns in the use and timing of chemotherapy and resection and factors associated with receipt of multimodality therapy in older patients with locoregional pancreatic cancer. Methods We used Surveillance, Epidemiology, and End Results-linked Medicare data (1992-2007) to identify patients with locoregional pancreatic adenocarcinoma. Multimodality therapy was defined as receipt of both chemotherapy and pancreatic resection. Logistic regression was used to determine factors independently associated with receipt of multimodality therapy. Log-rank tests were used to identify differences in survival for patients stratified by type and timing of treatment. Results We identified 10,505 patients with pancreatic adenocarcinoma. 5,358 patients (51.0%) received either chemotherapy or surgery, with 1,166 patients (11.1%) receiving both modalities. Resection alone was performed in 1,138 patients (10.8%), and chemotherapy alone was given to 3,054 (29.1%) patients. In patients undergoing resection as the initial treatment modality, 49.4% never received chemotherapy; 97.4% of patients who underwent chemotherapy as the initial treatment modality never underwent resection. The use of multimodality therapy increased from 7.4% of patients in 1992-1995 to 13.8% of patients in 2004-2007 (P <.0001). The 2-year survival was 41.0% for patients receiving multimodality therapy, 25.1% with resection alone, and 12.5% with chemotherapy alone (P <.0001). Of the patients receiving multimodality therapy, chemotherapy was delivered in the adjuvant setting in 93.1% and in the neoadjuvant setting in 6.9%, with similar 2-year survival with either approach (neoadjuvant vs adjuvant, 46.9% vs 40.6%; P =.16). Year of diagnosis, white race, less comorbidity, and no vascular invasion were independently associated with receipt of multimodality therapy. Conclusion Only half of older patients with locoregional pancreatic cancer receive any treatment, and fewer than one quarter of treated patients receive multimodality therapy. Nearly all patients receiving chemotherapy as the initial treatment modality did not undergo resection, whereas half of those undergoing resection first received chemotherapy. When multimodality therapy is used, the vast majority of patients had chemotherapy in the adjuvant setting with a similar survival, regardless of approach.

    Original languageEnglish (US)
    Pages (from-to)280-289
    Number of pages10
    JournalSurgery (United States)
    Volume156
    Issue number2
    DOIs
    StatePublished - 2014

    Fingerprint

    Adenocarcinoma
    Drug Therapy
    Therapeutics
    Pancreatic Neoplasms
    Survival
    Adjuvant Chemotherapy
    Medicare
    Blood Vessels
    Comorbidity
    Epidemiology

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. / Parmar, Abhishek D.; Vargas, Gabriela M.; Tamirisa, Nina P.; Sheffield, Kristin M.; Riall, Taylor S.

    In: Surgery (United States), Vol. 156, No. 2, 2014, p. 280-289.

    Research output: Contribution to journalArticle

    Parmar, Abhishek D. ; Vargas, Gabriela M. ; Tamirisa, Nina P. ; Sheffield, Kristin M. ; Riall, Taylor S. / Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. In: Surgery (United States). 2014 ; Vol. 156, No. 2. pp. 280-289.
    @article{633f70f1ec1541a18173c3911fd7a7bc,
    title = "Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma",
    abstract = "Introduction Multimodality therapy with chemotherapy and operative resection is recommended for patients with locoregional pancreatic cancer but is not received by many patients. Objective To evaluate patterns in the use and timing of chemotherapy and resection and factors associated with receipt of multimodality therapy in older patients with locoregional pancreatic cancer. Methods We used Surveillance, Epidemiology, and End Results-linked Medicare data (1992-2007) to identify patients with locoregional pancreatic adenocarcinoma. Multimodality therapy was defined as receipt of both chemotherapy and pancreatic resection. Logistic regression was used to determine factors independently associated with receipt of multimodality therapy. Log-rank tests were used to identify differences in survival for patients stratified by type and timing of treatment. Results We identified 10,505 patients with pancreatic adenocarcinoma. 5,358 patients (51.0{\%}) received either chemotherapy or surgery, with 1,166 patients (11.1{\%}) receiving both modalities. Resection alone was performed in 1,138 patients (10.8{\%}), and chemotherapy alone was given to 3,054 (29.1{\%}) patients. In patients undergoing resection as the initial treatment modality, 49.4{\%} never received chemotherapy; 97.4{\%} of patients who underwent chemotherapy as the initial treatment modality never underwent resection. The use of multimodality therapy increased from 7.4{\%} of patients in 1992-1995 to 13.8{\%} of patients in 2004-2007 (P <.0001). The 2-year survival was 41.0{\%} for patients receiving multimodality therapy, 25.1{\%} with resection alone, and 12.5{\%} with chemotherapy alone (P <.0001). Of the patients receiving multimodality therapy, chemotherapy was delivered in the adjuvant setting in 93.1{\%} and in the neoadjuvant setting in 6.9{\%}, with similar 2-year survival with either approach (neoadjuvant vs adjuvant, 46.9{\%} vs 40.6{\%}; P =.16). Year of diagnosis, white race, less comorbidity, and no vascular invasion were independently associated with receipt of multimodality therapy. Conclusion Only half of older patients with locoregional pancreatic cancer receive any treatment, and fewer than one quarter of treated patients receive multimodality therapy. Nearly all patients receiving chemotherapy as the initial treatment modality did not undergo resection, whereas half of those undergoing resection first received chemotherapy. When multimodality therapy is used, the vast majority of patients had chemotherapy in the adjuvant setting with a similar survival, regardless of approach.",
    author = "Parmar, {Abhishek D.} and Vargas, {Gabriela M.} and Tamirisa, {Nina P.} and Sheffield, {Kristin M.} and Riall, {Taylor S.}",
    year = "2014",
    doi = "10.1016/j.surg.2014.03.001",
    language = "English (US)",
    volume = "156",
    pages = "280--289",
    journal = "Surgery",
    issn = "0039-6060",
    publisher = "Mosby Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma

    AU - Parmar, Abhishek D.

    AU - Vargas, Gabriela M.

    AU - Tamirisa, Nina P.

    AU - Sheffield, Kristin M.

    AU - Riall, Taylor S.

    PY - 2014

    Y1 - 2014

    N2 - Introduction Multimodality therapy with chemotherapy and operative resection is recommended for patients with locoregional pancreatic cancer but is not received by many patients. Objective To evaluate patterns in the use and timing of chemotherapy and resection and factors associated with receipt of multimodality therapy in older patients with locoregional pancreatic cancer. Methods We used Surveillance, Epidemiology, and End Results-linked Medicare data (1992-2007) to identify patients with locoregional pancreatic adenocarcinoma. Multimodality therapy was defined as receipt of both chemotherapy and pancreatic resection. Logistic regression was used to determine factors independently associated with receipt of multimodality therapy. Log-rank tests were used to identify differences in survival for patients stratified by type and timing of treatment. Results We identified 10,505 patients with pancreatic adenocarcinoma. 5,358 patients (51.0%) received either chemotherapy or surgery, with 1,166 patients (11.1%) receiving both modalities. Resection alone was performed in 1,138 patients (10.8%), and chemotherapy alone was given to 3,054 (29.1%) patients. In patients undergoing resection as the initial treatment modality, 49.4% never received chemotherapy; 97.4% of patients who underwent chemotherapy as the initial treatment modality never underwent resection. The use of multimodality therapy increased from 7.4% of patients in 1992-1995 to 13.8% of patients in 2004-2007 (P <.0001). The 2-year survival was 41.0% for patients receiving multimodality therapy, 25.1% with resection alone, and 12.5% with chemotherapy alone (P <.0001). Of the patients receiving multimodality therapy, chemotherapy was delivered in the adjuvant setting in 93.1% and in the neoadjuvant setting in 6.9%, with similar 2-year survival with either approach (neoadjuvant vs adjuvant, 46.9% vs 40.6%; P =.16). Year of diagnosis, white race, less comorbidity, and no vascular invasion were independently associated with receipt of multimodality therapy. Conclusion Only half of older patients with locoregional pancreatic cancer receive any treatment, and fewer than one quarter of treated patients receive multimodality therapy. Nearly all patients receiving chemotherapy as the initial treatment modality did not undergo resection, whereas half of those undergoing resection first received chemotherapy. When multimodality therapy is used, the vast majority of patients had chemotherapy in the adjuvant setting with a similar survival, regardless of approach.

    AB - Introduction Multimodality therapy with chemotherapy and operative resection is recommended for patients with locoregional pancreatic cancer but is not received by many patients. Objective To evaluate patterns in the use and timing of chemotherapy and resection and factors associated with receipt of multimodality therapy in older patients with locoregional pancreatic cancer. Methods We used Surveillance, Epidemiology, and End Results-linked Medicare data (1992-2007) to identify patients with locoregional pancreatic adenocarcinoma. Multimodality therapy was defined as receipt of both chemotherapy and pancreatic resection. Logistic regression was used to determine factors independently associated with receipt of multimodality therapy. Log-rank tests were used to identify differences in survival for patients stratified by type and timing of treatment. Results We identified 10,505 patients with pancreatic adenocarcinoma. 5,358 patients (51.0%) received either chemotherapy or surgery, with 1,166 patients (11.1%) receiving both modalities. Resection alone was performed in 1,138 patients (10.8%), and chemotherapy alone was given to 3,054 (29.1%) patients. In patients undergoing resection as the initial treatment modality, 49.4% never received chemotherapy; 97.4% of patients who underwent chemotherapy as the initial treatment modality never underwent resection. The use of multimodality therapy increased from 7.4% of patients in 1992-1995 to 13.8% of patients in 2004-2007 (P <.0001). The 2-year survival was 41.0% for patients receiving multimodality therapy, 25.1% with resection alone, and 12.5% with chemotherapy alone (P <.0001). Of the patients receiving multimodality therapy, chemotherapy was delivered in the adjuvant setting in 93.1% and in the neoadjuvant setting in 6.9%, with similar 2-year survival with either approach (neoadjuvant vs adjuvant, 46.9% vs 40.6%; P =.16). Year of diagnosis, white race, less comorbidity, and no vascular invasion were independently associated with receipt of multimodality therapy. Conclusion Only half of older patients with locoregional pancreatic cancer receive any treatment, and fewer than one quarter of treated patients receive multimodality therapy. Nearly all patients receiving chemotherapy as the initial treatment modality did not undergo resection, whereas half of those undergoing resection first received chemotherapy. When multimodality therapy is used, the vast majority of patients had chemotherapy in the adjuvant setting with a similar survival, regardless of approach.

    UR - http://www.scopus.com/inward/record.url?scp=84904267009&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84904267009&partnerID=8YFLogxK

    U2 - 10.1016/j.surg.2014.03.001

    DO - 10.1016/j.surg.2014.03.001

    M3 - Article

    VL - 156

    SP - 280

    EP - 289

    JO - Surgery

    JF - Surgery

    SN - 0039-6060

    IS - 2

    ER -